drugset / Trial / NCT01114672

A Study of Oral Ergocalciferol to Treat Pruritis in Hemodialysis Patients

NCT01114672

RandomizedParallel-groupDouble-blindTreatment

Summary

Pruritis (itching) is common in many people with chronic renal failure on hemodialysis. There may be many different reasons for the pruritis. Efforts to treat the problem have not been very effective. Vitamin D levels have been found to be low in many hemodialysis patients. Since vitamin D plays an important role in the skin and is effective in treatment of certain skin conditions that involve pruritis, it may have a role in treatment of pruritis in hemodialysis patients. The objective of the investigators study is to determine the effect of supplementation with oral vitamin D2 (ergocalciferol) on pruritis in hemodialysis patients.

Timeline

Start
2010-07
Primary completion
2011-11
Completion
2012-02

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ergocalciferol Small molecule 50000 iu Oral

Indications

No indication recorded.